Burke CA, Dekker E, Lynch P, et al. - Researchers evaluated the safety and efficacy of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis. They performed stratification of patients on the basis of anatomical site with the highest polyp burden and surgical status; the strata were precolectomy (shortest projected time to disease progression), rectal or ileal pouch polyposis after colectomy (longest projected time), and duodenal polyposis (intermediate projected time). Thereafter, randomization was performed of a total of 171 patients in a 1:1:1 ratio to receive 750 mg of eflornithine, 150 mg of sulindac, or both once daily for up to 48 months. Outcomes indicated no significantly lower incidence of disease progression in correlation with the combination of eflornithine and sulindac than with either drug alone.